Structural genomics (SG) programs have developed during the last decade many novel methodologies for faster and more accurate structure determination. These new tools and approaches led to the determination of thousands of protein structures. The generation of enormous amounts of experimental data resulted in significant improvements in the understanding of many biological processes at molecular levels. However, the amount of data collected so far is so large that traditional analysis methods are limiting the rate of extraction of biological and biochemical information from 3D models. This situation has prompted us to review the challenges that remain unmet by SG, as well as the areas in which the potential impact of SG could exceed what has been achieved so far. 
Introduction
Structural biology provides invaluable information necessary for understanding the functions of living organisms at a molecular level. However, the number of known protein sequences is growing so rapidly that, despite enormous advances in structure determination protocols, the gap between genomic and structural information is widening. To counteract this trend, a number of structural genomics (SG) programs were created, with the aim of providing ways to limit such disparities. The original task for many public SG centers in the United States was to maximize the structural coverage of protein sequence space through careful target selection and bioinformatics tools, such as homology modeling. Unfortunately, even the most sophisticated bioinformatics tools are not able to classify many gene products, and approximately 30-40% of them are classified as 'hypothetical proteins' [1 ] .
SG centers are using (or have used) different approaches to structurally characterize the protein world as completely as possible. For example, the National Institutes of Health (NIH) Protein Structure Initiative (PSI and PSI2) centers focus on structural studies of the representative members of the largest proteins families [2] , proteins from human parasites [3] , and Mycobacterium tuberculosis [4 ] . The human proteome was chosen as the target for the Structural Genomics Consortium (SGC) and RIKEN [5 ] , while two National Institute of Allergy and Infectious Diseases (NIAID) funded centers (the Center for Structural Genomics of Infectious Diseases (CSGID) [6 ] and the Seattle Structural Genomics Center for Infectious Disease (SSGCID) [7 ] ) are determining the structures of proteins from major human pathogens. SPINE2, the successor of Structural Proteomics In Europe -SPINE [8] , concentrates on structures of complexes from signaling pathways linking immunology, neurobiology and cancer (http://www.spine2.eu/SPINE2/). Additionally, most SG centers have dedicated a significant part of their efforts to the development of high-throughput (and preferably high-output) methodology, which may now also be used for fast and more accurate determination of structures by both X-ray crystallography and NMR techniques in laboratories not involved in SG efforts. Work on thousands of target proteins has led to the development of efficient protocols for each of the steps of the structure determination process. New experimental protocols that were developed through SG efforts have shifted over time the so-called 'bottlenecks' in the pipeline, and it seems that, at present, the analysis of 3D structures in the context of all biological (functional) and bioinformatics information is the slowest step of the whole process. Similarly, many problems dealing with protein production, crystallization, and other steps on the road from sequence to function can be identified or even overcome by the analysis of all available biochemical and bioinformatics data.
During the last decade, SG efforts have shown that it is possible to create pipelines able to generate roughly 200 novel structures per year in a single center. Contrary to expectations, SG pipelines were able to solve many structures that were very difficult. For example, the Midwest Center for Structural Genomics (MCSG) structure [PDB code 3N99] has the best quality parameters among the structures solved to a similar resolution (2.4 Å ), despite having a molecular mass close to 1 MDa in the asymmetric unit.
In this review we would like to concentrate mainly on the application of X-ray diffraction in SG [9 ] , as this methodology is currently used for the determination of $80% of SG structures. We will address the challenges of SG programs and/or approaches that were not met or areas where the potential impact of SG could surpass that which has been achieved so far. The unmet challenges should not be treated as failures but rather as opportunities to open avenues to new, exciting research.
Protein production and crystallization
A significant part of the SG effort is concentrated on the production of soluble and pure proteins. Genes encoding such proteins are overexpressed in a variety of cell types (bacterial, yeast, insect, and mammalian), as well as in cell-free expression systems [10, 11] . The latter are currently considered to provide the most important alternative to conventional in vivo expression [12] , which has become especially useful in the production of isotopically labeled proteins for structure determination by NMR. Currently, a vast majority (83%) of over 280 protein structures deposited in the Protein Data Bank (PDB) and produced with the utilization of cell-free systems were determined by NMR. Most such proteins are of human origin ( Figure 1 ) and a majority of their structures were determined at RIKEN. Efforts to optimize expression have resulted in many new vectors, expression systems, and experimental protocols. Despite all these developments, the process from cloning a gene to producing milligram quantities of soluble protein requires substantial effort and resources, even for apparently 'easy' bacterial targets. A similar situation is also present in the case of crystallization, and it is not surprising that attrition at these two stages causes a reduction of the overall yield of SG pipelines [13] . A silver bullet for crystallization remains undiscovered, although technologies developed and/or used on a large scale by SG efforts have improved the process. These include surface entropy reduction [14 ] , large-scale reductive methylation of lysine residues [15 ] , in situ proteolysis [16 ,17 ] , nanolitre volume crystallization [18] [19] [20] [21] , and a significant degree of automation of the whole process.
A search of the literature and analysis of PDB deposits [22] shows that the advantage of the unusual stability of many target proteins originating from extremophilic bacteria has not been well exploited to date. Although temperature was shown to be an important factor affecting crystallization, there has been no reported systematic effort to use temperatures above ambient for preparation of proteins from thermophilic organisms such as Thermotoga maritima [22, 23] . This is rather surprising, since, based on analysis by the Joint Center for Structural Genomics (JCSG) of the crystallization conditions for several hundred proteins from T. maritima, it has been shown that for the two temperatures of crystallization tested (4 and 20 8C), the higher one gave 25% more hits [24] . Moreover, except for membrane proteins, there is no information about optimization by SG groups of crystallization screens toward particular groups or families of proteins. In contrast, multiple non-SG groups have used crystallization information in the Biological Macromolecule Crystallization Database (BMCD) to identify the best crystallization conditions for particular protein families [25, 26] . It seems that the first generation of automation inhibited the flexibility necessary to treat various groups of target proteins differently. For example, application of so-called crystallization chaperones has also been very limited, most likely due to their relatively high cost and to the need for time-demanding protocols [27, 28] .
Owing to the high degree of automation and to the application of databases, the results of SG crystallization experiments have been relatively well analyzed and both the successful and failed experiments could be considered in order to develop new ones or to modify existing experimental protocols [15 ,16 ,29,30,31 ] . In addition, SG deposits tend to contain more information on crystallization conditions than deposits coming from traditional structural biology laboratories. In the case of SG, 98% of PDB deposits contain information on crystallization, whereas such information is available for only 86% of non-SG deposits (93% of deposits after October 1, 2000). Such improvement in the completeness of PDB deposits improves the reliability of data mining approaches, especially those which are based on successful experiments. However, the lack of access to all failed experiments limits our ability to extract the entirety of the statistically useful information.
Quality of data and of the resulting structures Different SG centers not only choose different strategies for target selection, but also use different methodologies for structure determination. As has been noted, the average quality of X-ray structures solved by SG is the same or even better than the average quality of structures determined by traditional structural biology [32 ] . However, there are quite significant differences in the quality of experimental 3D structural models elucidated by various consortia and the reasons for such discrepancies merit analysis. Surprisingly, despite almost 5000 structures that have been solved by PSI centers, there is still no precise definition of the terms that could be universally used to assess the quality of macromolecular structures. In an ideal world the resolution should be used as the main parameter describing the accuracy of the model that is coming from a diffraction experiment. However, the resolution limit of diffraction data is not always determined consistently, or, for that matter, even correctly. In most cases, the reported resolution limit depends mainly on the experience of the experimenter, who uses data completeness, I/sI, and R merge values to decide which data to use in structure determination and refinement [33 ] . As a result, two structures reporting the same 'nominal' resolution may in fact have significantly different 'real' resolution limits, due to measurable differences in the mean I/sI in the highest resolution shell [34 ] . Structures that were determined using data cutoff at a resolution lower than the true crystal diffraction limits should be of higher quality than other structures determined at the same resolution, if no mistakes that would cancel the benefits of artificially lowered resolution have been made. Several SG centers (CSGID, JCSG, and SSGCID) make diffraction images publicly available. Availability of such 'raw' experimental data not only provides an opportunity to fully examine data quality, but also gives an opportunity to use data for the development of new crystallographic protocols and tools, as well as a unique opportunity to use such data for training purposes. Traditionally, it has been argued that prohibitive cost of storage makes such data availability impractical. In fact, the cost of the hardware to store the raw data from all PDB structures is now much lower than the cost of determining a single structure in the most efficient SG center [9 ] . The availability of raw diffraction data may further improve validation of macromolecular models.
Some SG centers have developed their own validation protocols, which in many cases use popular validation programs available to the structural biology community since the 1990s. MOLPROBITY [35] is probably the only recently developed validation program that has made a significant impact on the quality of structures. Utilization of this software has led to improvement of the overall quality of structures deposited in the PDB. However, there are still no generally accepted, well-defined criteria describing the quality of PDB deposits. It may be a missed opportunity that no quality standard was created before more than 5000 structures were deposited to the PDB by a single SG initiative (the PSI).
Mandatory deposition to the PDB of not only the coordinates, but also the experimental structure factors allows re-refinement of the published structures and independent evaluation of their quality. Unfortunately, the SG did not develop uniform procedures for the interpretation of electron density maps, which limits the usefulness of the PDB for a wider biomedical audience. Uniformity of interpretation is especially important for the map regions of relatively poor quality. For example, in situations where the electron density for an amino acid side chain is missing, three different model-building approaches can be utilized. In the first approach, the side chain is placed in a chemically correct, but arbitrary orientation and its mobility are represented by high B-factor values. The second approach is similar to the first one; however, the occupancy of the missing part of the residue is set to zero. In the third approach, the side chain of the amino acid model is removed outright. Despite various valid arguments, none of these approaches is significantly better than the others, although removal of the missing fragments is most probably the best way to 'transform' electron densities into an atomic model. This is especially true when one takes into account not only the mobility of side chains, but also the overall damage to the sample due to the radiation used for diffraction experiments [36 ] .
Such differences in interpretation of the electron density may have a deleterious effect on subsequent analysis of the deposited structures. In fact, one must remember that every improvement of the protocols and software used for analysis of diffraction images, structure refinement, and validation allows for the creation of better-fitting models. It was shown recently that a majority of the coordinates in the PDB with available structure factors can be refined further [37, 38] . One might conclude that comparisons of the structure quality at the moment of the deposition should be performed not against all available structures, but rather only against the recently deposited structures. Even in the cases where data collection was performed optimally, the resolution of the data is high and the Rfactor values of the model are low, there is no guarantee that the derived model is error-free [39 ] .
Currently, re-refinement is the best method for the validation of a structure deposited in the PDB (although not always the easiest or the fastest). One of the problems that may be encountered by a user of experimental data deposited in the PDB is the lack of a strict standard determining which and how data should be deposited. For example, a file containing reflection data may contain either experimental structure factors, intensities, or in some cases both. Even in a relatively easy case, such as data for a structure solved by SAD and refined using the same data set, it is not clear whether Bijvoet-pair-merged or Bijvoet-pair-unmerged data should be deposited. Moreover, in many cases structures solved with SAD by the incorporation of Se-Met not only include methionine residues in the deposited model instead of the selenomethionine residues, but also improper residues are used during entire refinement procedure. A similar situation is observed in the case of proteins containing polyhistidine affinity tags (His-tags). The reporting and treatment of His-tags is very inconsistent, and, in extreme cases, the His-tag is reported in the sequence but the electron density clearly corresponding to it is not modeled, or the His-tag is omitted from the sequence although there is clear electron density for it. Such inconsistencies affect data mining attempts, for example, aimed at analysis of the impact of the presence of a purification tag on crystallization. The lack of consistency is even more pronounced in more complicated situations, especially since the current form of the PDB header information does not allow for detailed description of the diffraction experiment. These inconsistencies cause situations where the originally reported R and R free values cannot be reproduced, for example due to missing information about the status of reflections [40] . However, thanks in part to the policy of the PSI SG initiative requiring deposition of structure factors along with structures to the PDB, protein crystallography rates above other methods in terms of having 'raw' experimental data available. The recent push for deposition of cryoEM maps to the EMDB (http://www.petitiononline.com/ cryoEM/petition.html) is at least 10 years behind the implementation of a universally adopted standard for submission of X-ray diffraction data to the PDB.
Homology modeling
Homology modeling is currently the most accurate computational technique able to generate three-dimensional models of proteins in cases when a de novo model derived from NMR or X-ray experiments is not available [41 ] . When sequence identity between the target and a template structure is low, determination of an accurate homology model becomes very difficult. In order to provide the largest possible number of templates for homology modeling, the PSI centers have concentrated their efforts on proteins with no known homologs in the PDB, defined as having less than 30% sequence identity to any protein with a deposited structure. Such a systematic effort to provide experimental data for structural coverage of genomes [1 ,2] resulted in a significant number of new templates for modeling [42, 43] . Millions of models are now easily available through PSI webpage (www.proteinmodelportal.org/), as well as through other large databases of protein models [44, 45] . Owing to their lack of sequence similarity to previously deposited structures, SG targets are ideal cases for CASP (CommunityWide Experiment on the Critical Assessment of Techniques for Protein Structure Prediction competition [46] ). In fact, in recent editions of CASP, SG groups have provided the vast majority (121 out of 128 in CASP8) of experimental structures used to assess the quality of homology modeling [47] .
Even if well-defined templates for domains are available, modeling of larger complexes may be problematic as the determination of the relative orientation of different domains may be very difficult. In many such cases the use of small-angle X-ray scattering and/or cryo-electron microscopy techniques has been shown to be beneficial [48] .
The PSI centers have been an invaluable source of structural data for tests of structure prediction algorithms. For example, 90% of targets in the CASP7 and CASP8 (Critical Assessment of Techniques for Proteins Structure Prediction) competitions originated from SG groups [47] . The structures of many new proteins have been found to be similar to already known structures despite the lack of detectable sequence similarity, and thus selection of these structures for SG efforts might be treated either as a failure of target selection for SG centers or as a success in the identification of new physicochemical ways of accommodating existing folds. However, it is possible that protein molecules could be described using some new concepts, such as, for example, the protein metastructure [49] .
Small molecule ligands
Almost 70% of all crystal structures deposited to the PDB include one or more ligand(s) [34 ] . In many cases, the ligands could be as simple as metal cations (such as magnesium or calcium), or anions (such as sulfate and phosphate), but quite often the ligands are large and complicated molecules. The presence of ligands may create serious problems during structure validation, as the standard validation tools are not able to assess the 'correctness' of many small molecule compounds. Taking into account that the functions of 26% of SG structures are unknown, it is also not surprising that SG structures contain unknown ligands more often than do those structures solved by traditional means (the fraction of structures with unknown ligands is 3.0% versus 0.2%, respectively). In many cases, annotations are simply wrong, which may be worse for biologists than no annotation at all. Careful analysis of the electron density and of the details of ligand-binding sites have led in some cases to the identification of the proper ligands and structure redeposition (e.g. 2NYD and 3LNL; 1PB6 and 3LOC). When performed correctly, such analysis, albeit timeconsuming, can provide considerable insights into the function of the protein in question [50] .
One example of often overlooked method for the identification of a bound ligand involves X-ray fluorescence measurements during data collection. Such experiments can provide unambiguous identification of metal ions, nevertheless do not answer the question of whether they are bound to the protein, or are simply present in solution. Rapid structure determination performed while the crystal is still mounted on the goniometer head allows for subsequent measurement(s) of anomalous differences, which can be used to generate a difference map that can precisely show the location of metal ions [51] . Unfortunately, these more complex experiments are performed only infrequently, despite the fact that 11% of SG structures contain transition metals (Cd, Co, Cu, Fe, Mn, Ni, and Zn). Our experience shows that fast structure determination is not only desirable, but also readily achievable in practice, and critical for determining whether sufficient data have been collected. The presence of ordered metals bound to a protein can also facilitate structure elucidation, if they are used for phasing. It should be readily apparent that proper identification of metal ions is a prerequisite for correct refinement and validation. The most common errors in metal ion refinement are caused by their misidentification during the refinement process. Most of these errors can be relatively easily spotted by analysis of distances between an ion and its coordinating atoms [52] . It is most likely that the lack of a proper validation tool capable of checking the geometrical likelihood of a metal-binding environment leads to a situation that the chemistry of metal coordination seems to be resolutiondependent. For example, the mean values for metaloxygen distances calculated using high-resolution or medium-resolution structures are typically different [52] . Such a phenomenon should not be observed if the refinement was carried out correctly. Furthermore, if proper metal-oxygen distance restraints are used, the standard deviations of distributions at different resolutions should be similar.
It is impossible to overestimate the importance of structure quality. Sometimes even a single incorrect structure may destroy data mining research. For example, analysis of the distances between Na + ions and their coordinating oxygen atoms for PDB structures determined at the resolution of 1.2 Å or better shows a bimodal distribution, in contrast to the unimodal distribution observed for equivalent distances in small molecule compounds (Figure 2) . A more detailed analysis shows that the second maximum is caused by a single PDB deposit, 3FJ0 (Figure 3) . Re-refinement of this structure indicates that many water molecules were wrongly assigned as sodium cations, and after reinterpretation of the electron density and correction of the model, this 'unusual' chemistry is no longer observed. The re-refined structure exhibits dramatically better R-factors, as well as more idealized geometrical parameters as analyzed by MOLPROBITY (Table 1) . This is a telling example that shows why the structures used in bioinformatics analyses should be extremely carefully reviewed, taking into account not only the resolution or scope of the set, but also other parameters describing the correctness of the models.
SG structures and drug discovery
One of the frequently mentioned potential benefits of protein crystallography is its use in the process of drug discovery and development. However, the discovery of novel drugs is still extremely challenging and it is well appreciated that the success rate of such projects can be very disappointing [53 ] . The lack of optimism becomes even more profound when it is considered that despite growing research and development expenditures, the number of newly approved drugs is decreasing [54] . SG projects have not yet significantly influenced this field of research [34 ] , although some preliminary results seem to be promising [4 ,55-57,58 ]. Moreover, it is possible that technologies developed by SG are not yet fully Crystal structure of b-glucosidase (PDB code 3FJ0) [76] . (a) Overall structure shown in ribbon representation, with a reaction intermediate shown in stick representation. (b) The structure has an unusually large number of Na + ions (purple spheres). Water molecules are marked as red spheres. The inset shows the binding site of the reaction intermediate in greater detail. The automatic procedures described in [37, 38] do improve the R factors, but do not correct the misidentification of waters as sodium ions: after automatic re-refinement, the resulting structure contains the same erroneous number of Na + atoms (252). implemented in the traditional and commercial laboratories. As shown in Figure 4 , SG delivers structures at a much faster rate than traditional structural biology. In the future, the fast delivery of structures, and, more importantly, structures of small molecule complexes of human proteins and/or proteins derived from different human pathogens may vastly benefit drug discovery programs [59, 60] .
SG had a definitely positive influence on homology modeling, but the same is not true for molecular docking. This is quite intriguing, since structures deposited by PSI Quality indicators for protein structures. (a) Clashscore (calculated with MOLPROBITY) as a function of resolution for all crystal structures in the PDB (box plots) versus the structures of protein targets used in the evaluation of templates in molecular docking [77] (red circles), high-resolution docking (blue circle) [78] and modeling (green circles) [79] . The box plots are labeled as follows: red lines mark the clashscore median for a particular resolution range, the boxes include structures with clashscores between the 25th and 75th percentile, and the dashed lines include structures with clashscores between 25% À 1.5IQR (the interquartile range) and 75% + 1.5IQR. (b) R-factors as a function of resolution for crystal structures of protein targets used in the evaluation of templates in molecular docking [77] , high-resolution docking [78] , and modeling [79] . Dark blue diamonds represent models with structure factors deposited, while light blue diamonds mark structures without structure factors. The blue line shows the linear regression of Rfactor as a function of resolution for all PDB structures, while the green, purple, yellow and red lines are the analogous linear regression fits for structures deposited by SG in general, MCSG, JCSG and CSGID respectively. (c) A Ramachandran plot for all structures of protein targets used in the evaluation of molecular docking [77] . This panel was created with COOT [80] .
centers could be very easily leveraged to create high quality test sets for docking studies. Even more importantly, such structures could be used for the validation of more challenging modeling studies, such as molecular docking to homology models [61,62 ,63] . In addition to high diversity, the representative structures selected for such studies should have the highest possible quality, a criterion which is almost never examined when test sets of structures are selected from the PDB ( Figure 5 ).
It is clear that the reliability of in silico screening of macromolecular ligands is a serious bottleneck in drug discovery research [34 ,64,65] . It is hard to estimate how the outcomes of in silico docking experiments are affected by the use of poor quality structures in analysis. Poor quality structures may negatively affect computational methods, both when they are used in docking studies and when they are used to test the algorithms implementing docking protocols. It is possible that some of the errors in the experimental models are eliminated during optimization of the models before ligand docking, especially when the ligand-binding site is known and its chemistry could be analyzed and corrected. These are areas that clearly merit further examination as SG efforts continue to expand and mature. Unfortunately, the use of poor quality structures cannot be avoided in some cases, as they represent the only available experimental models. In many cases, structures of very important drug targets were determined many years ago, using tools much less advanced than those currently available and used by SG. Many of such structures cannot be re-refined, since the structure factors were not deposited ( Figure 5 ).
From structure to function?
As many as 26% of all SG structures deposited to PDB are described as proteins of unknown function, or quite often their function is referred to as putative. The putative functions are most often assigned based on sequence similarity. High sequence identity usually allows for annotation transfer from a protein with a known function to the one that was newly directly investigated. Such transfer of an annotation is connected with some probability level that this annotation is true, yet the information about the probability that 'transferred' annotations are true is never shown. Experimenters must be especially careful checking gene or structure annotations which were done completely automatically. In many cases, curation of the data is necessary to avoid serious errors, caused, for example, by the use of the same names to describe different proteins across species [66] . Even a high degree of structural conservation does not guarantee that the function is also conserved. Some proteins having completely different functions may still have the same overall fold, and, if they are enzymes, very similar active sites.
Automation of the annotation process may not only fail at the sequence level, but may also be unsuccessful after experimental confirmation and publication of the protein's function. This effect is mainly caused by the fact that the function of a protein is annotated differently in different databases, and annotation of a protein in a single database may also be tied to homologous proteins as well. Automated correction of one database or of one record in a database may not be propagated to other databases or records, respectively. Despite the fact that information about a protein's function is explicitly stated in the title of the relevant publication, the function is sometimes marked as unknown elsewhere. Similarly, there are many PDB deposits that list unknown function in the deposit title despite of the fact that their authors published papers in which they established a function of the protein. Some efforts have used a collaborative method to expand and correct annotation information on sites such as Proteopedia [67] or TOPSAN (www.topsan.org). Another approach is to utilize the ISee concept, which uses an intuitive and interactive approach to disseminate structural information to the larger biomedical community [68] .
Structural data provided by the SG community should be linked to a particular function and biological process. It turns out that, in many cases, the availability of a structure alone does not necessarily lead to properly assigned function. This situation prompted the development of different bioinformatics approaches which should help in a search for functional clues [69] . The tools used to predict function from structure were developed not only by SG groups [70] , but also by many scientists not involved directly in SG [71] . It is not currently possible to evaluate the number of cases in which prediction of the function of SG targets from structure and/or sequence analysis was successful and subsequently verified by other experimental data [69] .
On the other hand, the availability of a large number of purified proteins of unknown function also resulted in the development of experimental approaches directed to function assignment. For that purpose, some SG centers created panels of enzymatic assays [72, 73] or tests for ligand binding [60, 74] .
Conclusions
During the last 10 years SG programs have generated enormous amounts of experimental data. It seems that a major bottleneck of the whole program is the ability to analyze data and immediately leverage the derived information for optimization of experimental pipelines. For example, large attrition rates on the path from gene to soluble protein and crystals could be treated, at least partially, as a failure of the target selection process. Many of the target proteins should not have been selected for high-throughput programs in the first place, for example, due to their intrinsic properties. Of course, for many targets the high probability of failure could not have been predicted at the time of their selection, and only later it was possible to learn from experimental techniques, such as light scattering or NMR, that such proteins might be difficult to crystallize.
Most probably, the major unmet challenge of SG is the insufficient rate of conversion of experimental data into biomedical information. In fact, this might be a result of the success of some SG programs that generated such vast amount of data that the currently available tools are not able to transform them into biologically useful information. Hopefully, creation of more sophisticated databases, like the PSI Structural Genomics Knowledgebase [75] , will improve extraction of information. The existence of such a database may also prompt creation of stricter and more precise standards, for example for determining deposition of structural data. It seems that such a step may be not only beneficial for traditional structural biology, but also necessary for the success of all large-scale analysis attempts.
